You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/64750
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAgapejev, Svetlana-
dc.contributor.authorDa Silva, Maria Dorvalina-
dc.contributor.authorUeda, Anete K.-
dc.date.accessioned2014-05-27T11:18:04Z-
dc.date.accessioned2016-10-25T18:13:48Z-
dc.date.available2014-05-27T11:18:04Z-
dc.date.available2016-10-25T18:13:48Z-
dc.date.issued1996-03-01-
dc.identifierhttp://dx.doi.org/10.1590/S0004-282X1996000100014-
dc.identifier.citationArquivos de Neuro-Psiquiatria, v. 54, n. 1, p. 82-93, 1996.-
dc.identifier.issn0004-282X-
dc.identifier.urihttp://hdl.handle.net/11449/64750-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/64750-
dc.description.abstractStudy of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days. Dextrochloropheniramine and ketoprofen were the adjuvant drugs Multiple symptoms were observed in 90 9% of patients. Intracranial hypertension was manifested in 90.9%. Hydrocephaly occurred in 86.4%. Evolution was satisfactory in 10 patients, 8 died and 4 had sequelae. Tomographic studies showed the appearance of an isolated IVth ventricle in 9 patients, after ventriculoperitoneal shunt, before ABZ treatment in 3 of them, during in 5 and after treatment in one. Median clinical follow-up duration was 10 months for the patients who died and 3-4 years for survivors. In 3 patients there was an increase in cyst size during the administration of the 15 mg/kg/day ABZ dose, which was not observed in any patient when the 30 mg/kg/day dose was used.en
dc.format.extent82-93-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectAlbendazole-
dc.subjectCysticercosis-
dc.subjectDextrochloropheniramine-
dc.subjectKetoprofen-
dc.subjectNeurocysticercosis-
dc.subjectSevere forms-
dc.subjectTreatment-
dc.subjectacetazolamide-
dc.subjectalbendazole-
dc.subjectdexchlorpheniramine-
dc.subjectketoprofen-
dc.subjectmannitol-
dc.subjectadolescent-
dc.subjectadult-
dc.subjectclinical article-
dc.subjectdrug efficacy-
dc.subjectfemale-
dc.subjecthuman-
dc.subjectmale-
dc.subjectneurocysticercosis-
dc.subjectAdolescent-
dc.subjectAdult-
dc.subjectAnthelmintics-
dc.subjectBrain Diseases-
dc.subjectChlorpheniramine-
dc.subjectFemale-
dc.subjectFollow-Up Studies-
dc.subjectHumans-
dc.subjectMale-
dc.subjectMiddle Aged-
dc.subjectPrognosis-
dc.subjectTomography, X-Ray Computed-
dc.titleSevere forms of neurocysticercosis: Treatment with albeimdazoleen
dc.typeoutro-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.description.affiliationDivision of Neurology Botucatu School of Medicine State University of São Paulo-
dc.description.affiliationDept. of Neurology and Psychiatry School of Medicine UNESP, P.O Box 540, 18618-000 Botucatu SP-
dc.description.affiliationUnespDept. of Neurology and Psychiatry School of Medicine UNESP, P.O Box 540, 18618-000 Botucatu SP-
dc.identifier.doi10.1590/S0004-282X1996000100014-
dc.identifier.scieloS0004-282X1996000100014-
dc.identifier.wosWOS:A1996TZ93500014-
dc.rights.accessRightsAcesso aberto-
dc.identifier.file2-s2.0-0029965675.pdf-
dc.relation.ispartofArquivos de Neuro-Psiquiatria-
dc.identifier.scopus2-s2.0-0029965675-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.